You are here

ARO-XDH

Orphan drug specialist Horizon looks to double down on its gout expertise with acquired rights to Arrowhead's RNAi med

Endpoints

Mon, 06/21/21 - 11:02 am

Horizon Therapeutics

Arrowhead Pharmaceuticals